Clinical Trial Update: Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating pharmacokinetic interactions between GSK3640254 and dolutegravir (DTG) in HIV infections; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Dolutegravir (dolutegravir)
• GSK3640254

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-03-19